Posts Tagged ‘LLBO’
Jim Holmes, CEO of Lifeline Biotechnologies, Inc., and Dr. Louis Keith, president of First Warning Systems(TM), Inc. are the Featured Guests in an Audio Interview at SmallCapVoice.com
December 30th, 2008 | Author: Tom
Podcast: Download (14.8MB)
SmallCapVoice.com, Inc. announces that a new audio interview featuring Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO), and its subsidiary, First Warning Systems™, Inc. is now available at SmallCapVoice.com. The interview can be heard here at http://smallcapvoice.com/blog/10-13-08-audio-interview-with-lifeline-biotechnologies-inc-otcpk-llbo/
SmallCapVoice.com is a corporate investor relations firm known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its client’s financial news releases. SmallCapVoice.com offers individual investors with the tools they need to make informed decisions about the stocks they are interested in. To learn more about SmallCapVoice.com, please visit http://www.smallcapvoice.com/services.html.
Posted in 
Tags: 
10-13-08 Audio Interview with Lifeline Biotechnologies, Inc. (OTCPK: LLBO)
October 13th, 2008 | Author: Tom
Podcast: Download (14.8MB)
Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System™, which was designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed: the development of the First Warning System™, the completion of clinical trials and FDA pre-marketing clearance. Additional information can be found on the Company’s website at: www.lbti.com.
Lifeline competes in the money markets for funds to support the development and commercialization of its products. The cost of funds, for early stage companies like Lifeline, is expensive and the terms have been, and may continue to be, dilutive.
